10 withdrawn. 10 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 10 | Withdrawn 10 |
Follow Hepatitis, Chronic: new trials by email Literature Review of Hepatitis, Chronic trials Research Report on Hepatitis, Chronic
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Single Patient Protocol for Donor HCV-positive to Recipient HCV-negative Kidney Transplant in a Patient at Risk for Loss of Dialysis Access Glecaprevir / Pibrentasvir Oral Tablet [Mavyret] - End Stage Renal Disease, Chronic Hepatitis c | Phase 4 | Withdrawn | Massachusetts General Hospital | 2020-11-13 | 2022-03-08 | |
| DAA in the Risk of Recurrence After Curative Treatment of HCC Ledipasvir 90mg/Sofosbuvir 400 mg, Ribavirin - Hepatocellular Carcinoma | Phase 4 | Withdrawn | Taipei Veterans General Hospital, Taiwan | 2016-11-01 | 2017-08-07 | |
| Impact of HCV Treatment on Neurocognitive Functions and Brain Metabolism DCV/ASV/BCV - Hepatitis C, Chronic | Phase 4 | Withdrawn | Kirby Institute | 2015-07-01 | 2016-06-03 | |
| A Study of the Safety and Effectiveness of Simeprevir and Sofosbuvir for Patients With HIV and Hepatitis C Sofosbuvir + Simeprevir - Hepatitis C, Chronic, HIV CDC Category A1 | Phase 4 | Withdrawn | University of California, San Francisco | 2014-08-01 | 2019-06-13 | |
| A Study of 48 Versus 96 Weeks of Peginterferon Alfa-2a [Pegasys] Treatment, With or Without Entecavir, in Patients With Chronic Hepatitis B. entecavir, peginterferon alfa-2a [Pegasys], placebo - Hepatitis B, Chronic | Phase 4 | Withdrawn | Hoffmann-La Roche | 2010-09-18 | 2017-02-17 | |
| Entecavir Plus Adefovir in Lamivudine-Resistant Patients Lamivudine, Entecavir, Adefovir - Hepatitis B, Chronic | Phase 4 | Withdrawn | Bristol-Myers Squibb | 2009-12-01 | 2015-09-01 | |
| Maraviroc Versus Etravirine In Combination With Antiretroviral Therapy In Drug Experienced HIV And Hepatitis Co-Infected Patients maraviroc, etravirine - Hepatitis B, Human Immunodeficiency Virus | Phase 4 | Withdrawn | ViiV Healthcare | 2009-03-01 | 2012-01-19 | |
| Efficacy and Safety of Telbivudine in Patients With Chronic Hepatitis B telbivudine, adefovir dipivoxil - Chronic Hepatitis B | Phase 4 | Withdrawn | Novartis | 2007-11-01 | 2012-05-02 | |
| Comparison of Telbivudine Versus Lamivudine on the Early Dynamics and Kinetics of Viral Suppression in Chronic Hepatitis B Lamivudine, Telbivudine - Hepatitis B, Chronic | Phase 4 | Withdrawn | University of Ulm | 40 | 2009-04-20 | |
| Trial of Telbivudine Combination Therapy vs. Continued Adefovir Monotherapy Telbivudine, Adefovir, Tenofovir - Chronic Hepatitis B | Phase 4 | Withdrawn | Novartis Pharmaceuticals | 2015-03-09 |
Hepatitis B, Chronic (5) · Hepatitis C, Chronic (5) · Hepatitis C (3) · Acquired Immunodeficiency Syndrome (1) · Carcinoma, Hepatocellular (1) · Hepatitis (1) · Hepatitis B (1) · Kidney Failure, Chronic (1) · Recurrence (1)
Blood-Borne Infections (10) · Chronic Disease (10) · Communicable Diseases (10) · Digestive System Diseases (10) · Disease Attributes (10) · Hepatitis, Viral, Human (10) · Infections (10) · Liver Diseases (10) · Pathologic Processes (10) · Pathological Conditions, Signs and Symptoms (10) · Virus Diseases (10) · Hepatitis (9) · DNA Virus Infections (6) · Hepadnaviridae Infections (6)
Telbivudine (3) · Lamivudine (2) · Sofosbuvir (2) · adefovir (2) · adefovir dipivoxil (2) · entecavir (2) · 8-cyclohexyl-N-((dimethylamino)sulfonyl)-1,1a,2,12b-tetrahydro-11-methoxy-1a-((3-methyl-3,8-diazabicyclo(3.2.1)oct-8-yl)carbonyl)cycloprop(d)indolo(2,1-a)(2)benzazepine-5-carboxamide (1) · Maraviroc (1) · Ribavirin (1) · Simeprevir (1) · Tenofovir (1) · asunaprevir (1) · daclatasvir (1) · etravirine (1) · glecaprevir (1)
Bristol-Myers Squibb (1) · Hoffmann-La Roche (1) · Kirby Institute (1) · Massachusetts General Hospital (1) · Novartis (1) · Novartis Pharmaceuticals (1) · Taipei Veterans General Hospital, Taiwan (1) · University of California, San Francisco (1) · University of Ulm (1) · ViiV Healthcare (1)
United States (4) · Australia (1) · Canada (1) · Germany (1) · Poland (1)
Anne Luetkemeyer, MD (1) · Gregory Dore, BSc, MBBS, FRACP, MPH, PhD (1) · Nektarios Dikopoulos, MD (1) · Yi-Hsiang Huang, MD, PhD (1)
2009 (1)